{"product_id":"rwe-in-gene-therapy-payer-views","title":"RWE in Gene Therapy: Payer Views","description":"\u003cp\u003eRWE in Gene Therapy: Payer Views\u003c\/p\u003e \n\n\u003cp\u003eHow to harness RWE to win payer support for gene therapies\u003c\/p\u003e\n\n\u003cp\u003eGene therapy developers are looking beyond rare diseases to treat a broader range of conditions. While payers are positive for new therapies that treat unmet clinical need there is a growing anxiety: can the cost of these novel therapies be afforded and justified? Payers want real-world evidence (RWE) that informs their decision making, but what evidence, where can it be found and what action can pharma take? This report explores why RWE will increasingly play a critical role in payer assessment of gene therapies and the practical strategies pharma can implement.\u003c\/p\u003e\n\n\u003cp\u003eCompanies\u003c\/p\u003e\n\n\u003cp\u003eAmgen, Novartis, GlaxoSmithKline, Janssen Biotech, Bristol Myers Squibb, Biogen, Spark Therapeutics, BioMarin Pharmaceutical, Bluebird Bio, CSL Behring, AveXis, Kite Pharma, uniQure, PTC Therapeutics, Celgene, Juno Therapeutics, Orchard Therapeutics\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"January, 2023 \/ - \/ MCW16226974","offer_id":47645902766386,"sku":null,"price":7140.0,"currency_code":"USD","in_stock":true}],"url":"https:\/\/www.hardmanwell.com\/products\/rwe-in-gene-therapy-payer-views","provider":"HARDMAN AND WELL MANAGEMENT CONSULTANCIES L.L.C","version":"1.0","type":"link"}